Loading
A phase 1/2 trial of Carboplatin, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by BlossomHill Therapeutics, now recruiting.
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations is a phase 1/2 interventional study registered as NCT06706076 by BlossomHill Therapeutics, with 675 participants planned, started 2025-01-09 and due to reach its primary completion in 2029-01-31. Interventions recorded: BH-30643, BH-30643 combo therapy with Carboplatin/Pemetrexed, BH-30643. Conditions listed: NSCLC (Advanced Non-small Cell Lung Cancer). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.
Shares HER2-mutant non-small-cell lung cancer, Pemetrexed, Carboplatin, Small-cell lung cancer.
Shares HER2-mutant non-small-cell lung cancer, Pemetrexed, Carboplatin, Small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/